ReviewOncology letters2026
Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Small Extracellular Vesicles (sEV) in Surgical Drain Fluids of Oral Squamous Cell Carcinoma Patients Carry Luminal and Surface DNA.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating cell-free DNA (cfDNA) has emerged as a valuable non-invasive biomarker that provides unique insights into the spatial and temporal heterogeneity of tumors, serving a key role in cancer precision medicine. Applications of cfDNA include detecting disease progression before clinical and radiological confirmation, identifying actionable genomic alterations, monitoring treatment response, revealing mechanisms of treatment resistance and assessing prognosis. The latest progress in research on the biological characteristics of cfDNA has provided unprecedented molecular insights into cancer diagnosis and treatment, thereby markedly expanding its clinical application scope. The present review explored the latest findings in cfDNA biology and its applications in early diagnosis, treatment monitoring and prognostic assessment of breast cancer. The present review proposed a novel staged transformation strategy guided by the disease progression stage of breast cancer and the maturity of cfDNA technology. The present review aimed to systematically and efficiently promote the application of cfDNA in the full-cycle management of breast cancer. Furthermore, the present review predicted cutting-edge directions such as multi-omics integration, artificial intelligence assistance and ethical considerations. Although cfDNA holds notable promise, its clinical translation is still limited by low-abundance signals in early-stage tumors, insufficient detection standardization and the complexity of bioinformatics interpretation. The present review was based on the integration of existing evidence; however, majority of studies are still retrospective or small-sample prospective, indicating a need to elevate the evidence level. Future research should focus on developing ultra-high-sensitivity multi-omics technology, establishing an international standardization system and verifying the actual effectiveness of cfDNA in guiding clinical decisions through large-scale prospective clinical trials. The ultimate goal is to realize the comprehensive application of cfDNA in early screening and personalized treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.